Introduction
NEUROENDOCRINE TUMOURS
Peptide receptor radionuclide therapy (PRRT) with radiolabelled somatostatin receptor (SSTR) agonists has shown to be well tolerated and effective, thereby becoming integral in management of advanced neuroendocrine tumours (NETs) [[We present the results of a phase I/II study evaluating the safety and efficacy of [